|
FT Raymond James Multicap Growth Equity ETF
|
||||||||||||||||||
- Description
- Performance
- Comps
Fundamentals
Valuation
Rating
| RJMG is an actively managed portfolio of US growth stocks rated as strong buy or outperform by the manager's proprietary equity research model. |
| Category | US Equities |
| Fund Sponsor | First Trust |
| Website | www.ftportfolios.com/Retail/Etf/EtfSummary.aspx?Ticker=RJMG |
| Inception date | Jan 16, 2024 |
| Assets (mns) | $11 |
| Currency | USD |
| Expense ratio | 85 bp |
| Distributions |
| Regulation | Open-Ended Fund |
| Custodian | |
| Weighting | |
| Index replication | |
| Uses derivatives | No |
| Options available | Yes |
| No. of constituents | 1 |
| Wgt avg mkt cap (mns) | $349,588 |
| Large cap (>$10bn) | 84.7% |
| Mid cap ($2-10bn) | 12.8% |
| Small cap (<$2bn) | 2.5% |
| Developed mkts | 100.0% |
| Emerging mkts | 0.0% |
| US DOLLAR | 100.0 % | Total | 100.0 % |
|---|
| 0.0 % |
HISTORICAL PERFORMANCE 

| Custom date range | Compare to | ||
| thru |
| Year-to-date | 1 year | 5 years | 10 years | Since Incep. |
| 15.0% | 15.0% | -- | -- | 21.3% |
| versus... | Beta | R-squared |
| S&P500 | 1.11 | 87% |
| MSCI EAFE | 1.07 | 58% |
| MSCI Emg. Mkts. | 0.97 | 54% |
| Recent close | $27.59 |
| 30d moving avg. | $27.15 |
| Annualized volatility | 17.7% |
| Short interest (ETF) | 0.0% |
| Relative strength (RSI) | 57 |
| Avg. volume (thou.) | 4 |
| Turnover | 1.0% |
| Bid/Ask (% of price) | 0.23% |
| ADV underlying (mns) | $59,372 |
| There were no matches found with other funds under coverage. |
Content on this tab for subscribers only**
RESULTS & ESTIMATES
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | |
|---|---|---|---|---|---|---|---|
| Sales per share | ** | ** | ** | ** | ** | ** | ** |
| Earnings per share | ** | ** | ** | ** | ** | ** | ** |
Dividends per share ![]() |
** | ** | ** | ** | ** | ** | ** |
| Book value per share | ** | ** | ** | ** | ** | ** | ** |
| Sales per share growth | **% | **% | **% | **% | **% | **% | |
| EPS growth | **% | **% | **% | **% | **% | **% |
| Sales per share growth | **% | **% | **% | **% | **% | **% | |
| EPS growth | **% | **% | **% | **% | **% | **% |
OTHER FUNDAMENTAL METRICS
| Long term EPS growth est. | **% | Debt-to-equity | **x | |
| Asset turnover | **% | Assets-to-equity | **x |
| *Six months ago = 100 |
Content on this tab for subscribers only
VALUATION METRICS
| 2024 | 2025E | 2026E | |
|---|---|---|---|
| Price-to-sales | ** | ** | ** |
| Price-to-earnings | ** | ** | ** |
| Price-to-cash flow | ** | ** | ** |
| Price-to-growth | ** | ** | ** |
| Price-to-book value | ** | ** | ** |
| Yield | ** | ** | ** |
Historical valuation trends
| Forward multiple: |
FT Raymond James Multicap Growth Equity ETF | |||
| Relative to: |
S&P500 | MSCI EAFE | MSCI Emg. Mkts. | Other ETF: |
AVOID |
| Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant. |
|
ALTAR Score™
|
MODERN PORTFOLIO THEORY
![]() |
||||||||||||||||||||
CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
|
||||||||||||||
